We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Insurers are increasingly denying prescriptions of direct-acting antiviral (DAA) drugs for hepatitis C virus treatment, according to a study published online June 7 in Open Forum Infectious Diseases.
The project, conducted in collaboration with the Arkhangai Province Health Department in Mongolia has managed to cure and control liver disease caused by viral HCV amongst the population in Arkhangai.